Fig. 5
From: Oral splicing modulator branaplam in Huntington’s disease: a phase 2 randomized controlled trial
Percentage change from baseline in volumetric MRI (safety analysis set). a, Lateral ventricle. b, Whole brain. c, Caudate. The results exclude participants with subdural hematoma. Numbers are means and data points are means (s.e.). The red diamond represents a single data point from one placebo participant who had an MRI at Week 53. TRACK-HD, observational TRACK-HD study used as external control arm24.
